Telomir Selects Linical CRO for Phase 1/2 TNBC Trial Targeting Q1 2027 Start

Telomir Pharmaceuticals announced on November 18 that it has entered a Master Services Agreement with global contract research organization Linical to facilitate a Phase 1/2 clinical trial for its investigational drug, Telomir-Zn, targeting advanced or metastatic triple-negative breast cancer (TNBC), with patient enrollment targeted for the first quarter of 2027.

Telomir-Zn Targets Metal Balance to Reactivate Genes

  • Targeted Innovation: Telomir-Zn is an oral therapy that focuses on “intracellular metal homeostasis”—or the balance of metal ions like iron within cells—to potentially reactivate tumor suppressor genes that cancer cells have silenced.
  • Operational Strategy: By partnering with a specialized CRO, Telomir aims to streamline the complex logistics of early-phase oncology, including site activation, patient recruitment, and biometrics, to avoid common delays in first-in-human studies.
  • Clinical Context: This study enters a competitive landscape where recent regulatory approvals, such as datopotamab deruxtecan in May 2026, have already established new benchmarks for treating patients who do not respond to traditional PD-1/PD-L1 inhibitor therapies, as noted by Clinical Trial Vanguard.

Operational Partnership for Early-Phase Oncology

The selection of Linical as the primary research partner is a move to mitigate the risks inherent in early-stage drug development. According to Telomir Pharmaceuticals, approximately half of Linical’s two decades of oncology experience is concentrated specifically in early-phase clinical trials.

This matters for a small, emerging-growth company because it puts the entire "full stack" of trial management—from coordinating investigators to handling regulatory support—into a single operational framework.

“We selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development,” said Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals. “With our clinical trial agreements now executed, we are focused on advancing toward clinical initiation in the first quarter of 2027 and evaluating the potential of our novel oral epigenetic therapy in patients with triple-negative breast cancer.”

Distinct Mechanisms in TNBC

Triple-negative breast cancer is defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). Because these tumors do not respond to hormone therapies or HER2-targeted drugs, the current FDA-approved treatment options often rely on antibody-drug conjugates (ADCs) like sacituzumab govitecan.

Telomir-Zn proposes an entirely different mechanism of action by modulating the availability of intracellular iron, an element that some TNBC cells rely on for rapid growth and epigenetic regulation.

Development Stage Focus Operational Milestone
Preclinical Iron-dependent epigenetic enzymes Antitumor activity observed in models
Phase 1/2 Safety, tolerability, PK/PD Linical partnership initiated
Clinical Initiation First-in-human study Targeted for Q1 2027

First-Quarter 2027 Start Faces Timeline Volatility

While the company has formally committed to a first-quarter 2027 start date, industry observers emphasize the volatility of early-phase oncology timelines. As reported by Clinical Trial Vanguard, site activation and Institutional Review Board (IRB) approvals often dictate the actual pace of enrollment. The industry standard for these trials frequently sees “first-patient-in” dates shift due to the technical rigor required for site selection in metastatic oncology programs.

“Our CRO team brings extensive experience in oncology and early-phase clinical development to this partnership, and we look forward to helping Telomir advance their important clinical program,” said Clareece West, President at Linical, according to Nasdaq. The success of this trial will be determined by whether the preclinical biological promise of iron-dynamic modulation translates into measurable clinical efficacy in human subjects.

Telomir Pharmaceuticals, which is headquartered in Miami, Florida, was incorporated in 2021. Originally founded under the name Metallo Therapies Inc., the company underwent a formal name change in October 2022 before completing its initial public offering in February 2024.

As a preclinical-stage biotechnology firm, the organization is primarily known for developing small-molecule therapeutics that target the biological drivers of aging. Its research pipeline spans a wide range of age-related conditions, including Type 2 diabetes, Alzheimer’s disease, and Progeria, alongside its work in oncology and epigenetic regulation.

Investigational Drug Unavailable Outside Trials

Telomir-Zn remains an investigational agent; it is not currently available for clinical use outside of approved trials. Patients with advanced or metastatic TNBC should discuss their eligibility for clinical trials with their oncologist. Potential participants must be aware that early-phase trials are designed primarily to assess safety and dosage (tolerability) rather than definitive cure.

Patients with pre-existing metabolic disorders or those currently undergoing intensive chemotherapy should consult their medical team to understand how experimental epigenetic therapies may interact with their current treatment regimen or exacerbate underlying health conditions.

References

  • U.S. Food and Drug Administration. FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic TNBC.
  • Clinical Trial Vanguard.
  • Telomir Pharmaceuticals. Telomir Pharmaceuticals has selected Linical to support its FDA-cleared Phase 1/2 clinical trial of Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer.
Photo of author

Health Desk

Health Desk at Archyde.

RTÉ and All the Food Reveal Dublin’s Best Festive Sambos for Christmas